(ARGX) argenx - Ratings and Ratios
Therapies, Treatments, Medications, Autoimmune Diseases, Biopharmaceuticals
ARGX EPS (Earnings per Share)
ARGX Revenue
Description: ARGX argenx
argenx SE is a commercial-stage biopharma company that develops therapies for autoimmune diseases. The company has a diverse pipeline of treatments for various conditions, including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. Its commercial products, VYGART and VYGART HYTRULO, have shown promise in treating these conditions.
From a business perspective, argenx has established strategic collaborations with multiple partners, including OncoVerity, LEO Pharma, and AbbVie, to advance its research and development efforts. This diversification of partnerships reduces dependence on a single partner and enhances the companys potential for growth. Key performance indicators (KPIs) to monitor include revenue growth from its commercial products, the number of ongoing clinical trials, and the expansion of its partnerships.
The companys research and development pipeline is robust, with multiple candidates in various stages of development, targeting a range of autoimmune diseases. Notable candidates include efgartigimod, empasiprubart, and ARGX-119, which are being developed for conditions such as seronegative and ocular gMG, thyroid eye diseases, and congenital myasthenic syndrome. The progress of these candidates in clinical trials will be crucial in determining the companys future growth prospects.
From a financial perspective, argenx has a market capitalization of $34.4 billion, indicating a significant presence in the biotechnology industry. The companys price-to-earnings ratio (P/E) is 34.25, and its forward P/E is 57.47, suggesting that investors have high expectations for its future earnings growth. The return on equity (RoE) of 25.75% indicates that the company is generating strong returns for its shareholders. Other KPIs to monitor include the companys cash burn rate, research and development expenses as a percentage of revenue, and the ratio of debt to equity.
To further evaluate argenxs potential, it is essential to analyze its financial statements, including its income statement, balance sheet, and cash flow statement. Key metrics to examine include revenue growth, gross margin, operating expenses, and cash flow from operations. Additionally, monitoring the companys guidance, analyst estimates, and industry trends will provide valuable insights into its future prospects.
ARGX Stock Overview
| Market Cap in USD | 47,015m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2017-05-18 |
ARGX Stock Ratings
| Growth Rating | 73.6% |
| Fundamental | 82.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 17.8% |
| Analyst Rating | 4.59 of 5 |
ARGX Dividends
Currently no dividends paidARGX Growth Ratios
| Growth Correlation 3m | 94.7% |
| Growth Correlation 12m | 32.7% |
| Growth Correlation 5y | 91.8% |
| CAGR 5y | 26.91% |
| CAGR/Max DD 3y | 0.70 |
| CAGR/Mean DD 3y | 3.39 |
| Sharpe Ratio 12m | 0.32 |
| Alpha | 0.07 |
| Beta | 0.427 |
| Volatility | 33.06% |
| Current Volume | 269.4k |
| Average Volume 20d | 345.8k |
| Stop Loss | 729.7 (-3%) |
| Signal | 0.78 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (1.37b TTM) > 0 and > 6% of Revenue (6% = 219.5m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 16.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 130.9% (prev 198.7%; Δ -67.78pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 479.8m <= Net Income 1.37b (YES >=105%, WARN >=100%) |
| Net Debt (-2.04b) to EBITDA (502.7m) ratio: -4.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (65.7m) change vs 12m ago 10.53% (target <= -2.0% for YES) |
| Gross Margin 74.97% (prev 65.63%; Δ 9.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 61.11% (prev 39.50%; Δ 21.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 111.5 (EBITDA TTM 502.7m / Interest Expense TTM 3.64m) >= 6 (WARN >= 3) |
Altman Z'' 3.27
| (A) 0.67 = (Total Current Assets 5.83b - Total Current Liabilities 1.04b) / Total Assets 7.18b |
| (B) -0.16 = Retained Earnings (Balance) -1.16b / Total Assets 7.18b |
| (C) 0.07 = EBIT TTM 405.9m / Avg Total Assets 5.99b |
| (D) -0.99 = Book Value of Equity -1.07b / Total Liabilities 1.08b |
| Total Rating: 3.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.21
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 1.10% = 0.55 |
| 3. FCF Margin 12.94% = 3.24 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.11 = 2.49 |
| 6. ROIC - WACC 30.16% = 12.50 |
| 7. RoE 27.50% = 2.29 |
| 8. Rev. Trend 42.78% = 3.21 |
| 9. EPS Trend 88.75% = 4.44 |
What is the price of ARGX shares?
Over the past week, the price has changed by -1.91%, over one month by +13.76%, over three months by +36.48% and over the past year by +39.85%.
Is argenx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARGX is around 831.81 USD . This means that ARGX is currently undervalued and has a potential upside of +10.57% (Margin of Safety).
Is ARGX a buy, sell or hold?
- Strong Buy: 14
- Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 810.8 | 7.8% |
| Analysts Target Price | 810.8 | 7.8% |
| ValueRay Target Price | 919.9 | 22.3% |
Last update: 2025-09-12 04:31
ARGX Fundamental Data Overview
CCE Cash And Equivalents = 3.93b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 38.7647
P/E Forward = 30.6748
P/S = 15.0651
P/B = 7.6592
P/EG = 1.3033
Beta = 0.001
Revenue TTM = 3.66b USD
EBIT TTM = 405.9m USD
EBITDA TTM = 502.7m USD
Long Term Debt = 37.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 15.2m USD (from shortTermDebt, last quarter)
Debt = 53.1m USD (Calculated: Short Term 15.2m + Long Term 37.9m)
Net Debt = -2.04b USD (from netDebt column, last quarter)
Enterprise Value = 43.14b USD (47.02b + Debt 53.1m - CCE 3.93b)
Interest Coverage Ratio = 111.5 (Ebit TTM 405.9m / Interest Expense TTM 3.64m)
FCF Yield = 1.10% (FCF TTM 473.5m / Enterprise Value 43.14b)
FCF Margin = 12.94% (FCF TTM 473.5m / Revenue TTM 3.66b)
Net Margin = 37.50% (Net Income TTM 1.37b / Revenue TTM 3.66b)
Gross Margin = 74.97% ((Revenue TTM 3.66b - Cost of Revenue TTM 915.5m) / Revenue TTM)
Tobins Q-Ratio = -40.26 (set to none) (Enterprise Value 43.14b / Book Value Of Equity -1.07b)
Interest Expense / Debt = 2.12% (Interest Expense 1.13m / Debt 53.1m)
Taxrate = -878.0% (set to none) (-747.9m / 85.2m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 5.60 (Total Current Assets 5.83b / Total Current Liabilities 1.04b)
Debt / Equity = 0.01 (Debt 53.1m / last Quarter total Stockholder Equity 6.10b)
Debt / EBITDA = 0.11 (Net Debt -2.04b / EBITDA 502.7m)
Debt / FCF = 0.11 (Debt 53.1m / FCF TTM 473.5m)
Total Stockholder Equity = 4.99b (last 4 quarters mean)
RoA = 19.12% (Net Income 1.37b, Total Assets 7.18b )
RoE = 27.50% (Net Income TTM 1.37b / Total Stockholder Equity 4.99b)
RoCE = 8.08% (Ebit 405.9m / (Equity 4.99b + L.T.Debt 37.9m))
RoIC = 30.16% (Ebit 405.9m / (Assets 7.18b - Current Assets 5.83b))
WACC = unknown (E(47.02b)/V(47.07b) * Re(7.59%)) + (D(53.1m)/V(47.07b) * Rd(2.12%) * (1-Tc(none)))
Shares Correlation 3-Years: 83.97 | Cagr: 1.59%
Discount Rate = 7.59% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈473.5m ; Y1≈310.9m ; Y5≈142.2m
Fair Price DCF = 45.66 (DCF Value 2.79b / Shares Outstanding 61.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 88.75 | EPS CAGR: 0.0% | SUE: 5.34 | # QB: True
Revenue Correlation: 42.78 | Revenue CAGR: 101.5%
Additional Sources for ARGX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle